Apatinib is an oral small molecule tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), which exhibits some efficacy in triple-negative and non-triple-negative metastastic breast cancer by monotherapy (10, 11). The gene discussed is KDR; the disease is breast carcinoma.